PathAI
Founded Year
2016Stage
Series C | AliveTotal Raised
$255MLast Raised
$165M | 4 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-38 points in the past 30 days
About PathAI
PathAI provides artificial intelligence (AI)-powered research tools and services for pathology. It delivers the diagnosis and treatment of cancer by leveraging modern approaches in machine learning. The company offers biopharmacy lab services, clinical development services, drug and diagnostic development, and more. It was founded in 2016 and is based in Boston, Massachusetts.
Loading...
ESPs containing PathAI
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The healthcare AI model developers market creates specialized AI models for clinical and administrative applications in healthcare settings. These include foundational models and large language models designed specifically for healthcare use cases such as revenue cycle management, medical imaging, and clinical insights generation. Companies in this market leverage their respective AI models to add…
PathAI named as Challenger among 14 other companies, including Google, Microsoft, and NVIDIA.
Loading...
Research containing PathAI
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned PathAI in 5 CB Insights research briefs, most recently on Nov 27, 2024.
Expert Collections containing PathAI
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
PathAI is included in 4 Expert Collections, including Digital Health 50.
Digital Health 50
450 items
The most promising digital health startups transforming the healthcare industry
Digital Health
11,305 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
463 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Artificial Intelligence
7,221 items
PathAI Patents
PathAI has filed 18 patents.
The 3 most popular patent topics include:
- machine learning
- clusters of differentiation
- artificial neural networks
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/1/2022 | 12/24/2024 | Diseases of liver, Hepatology, Continuous distributions, Artificial neural networks, Machine learning | Grant |
Application Date | 2/1/2022 |
|---|---|
Grant Date | 12/24/2024 |
Title | |
Related Topics | Diseases of liver, Hepatology, Continuous distributions, Artificial neural networks, Machine learning |
Status | Grant |
Latest PathAI News
Mar 25, 2025
United States and Canadian Academy of Pathology (USCAP) 114th Annual Meeting Company to present key research advancing digital pathology and host a networking event, H&E by the Sea, on March 25th at 6:00 p.m. ET at Nautilus Pier 4 March 25, 2025 09:00 ET PathAI BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered pathology solutions, today announced its participation in the United States and Canadian Academy of Pathology (USCAP) 114th Annual Meeting, taking place March 22–27, 2025, in Boston, Massachusetts. PathAI innovation will be highlighted in two oral presentations showcasing advancements in AI-driven pathology, including novel solutions for tumor detection and automated collagen quantification. “We are thrilled to share our latest research at USCAP 2025, highlighting how AI can enhance pathology workflows and improve accuracy,” said Andy Beck, MD, PhD, CEO, and co-founder of PathAI. “Through these presentations, we aim to demonstrate the power of AI-driven insights in transforming pathology and advancing precision medicine.” PathAI’s scientific oral presentations' key highlights: Title: Evaluation of an AI-Powered Digital Pathology Tool for Automated Tumor Detection and Case Prioritization PathAI will present data on an AI-powered digital pathology tool designed for automated tumor detection and case prioritization. This deep-learning model, trained on over 48,000 whole-slide images across 25 tissue types, demonstrates high sensitivity (0.86) and specificity (0.92) in identifying cancerous cases. The model’s potential to streamline pathology workflows and improve time to first review for malignant cases will be discussed. Title: Quantitative Multimodal Anisotropy Imaging (QMAI) Unveils and Quantifies Morphological Collagen Across Multiple Organ Systems - Partner Presentation with Eli Lilly A novel technique, Quantitative Multimodal Anisotropy Imaging (QMAI), will be highlighted for its ability to automate collagen quantification in H&E-stained slides. The study demonstrates how QMAI-derived collagen metrics correlate with pathologist assessments and distinguish diseased from normal tissues in ulcerative colitis and Crohn’s disease. The technique’s potential in fibrosis research and precision medicine will be explored. Other Presentations & Posters Include
PathAI Frequently Asked Questions (FAQ)
When was PathAI founded?
PathAI was founded in 2016.
Where is PathAI's headquarters?
PathAI's headquarters is located at 1325 Boylston Street, Boston.
What is PathAI's latest funding round?
PathAI's latest funding round is Series C.
How much did PathAI raise?
PathAI raised a total of $255M.
Who are the investors of PathAI?
Investors of PathAI include General Catalyst, Refactor Capital, General Atlantic, KdT Ventures, Bristol-Myers Squibb and 15 more.
Who are PathAI's competitors?
Competitors of PathAI include Azra AI, Deciphex, Primaa, Perspectum, Aignostics and 7 more.
Loading...
Compare PathAI to Competitors
Paige specializes in the development of digital pathology platforms and generative AI applications within the healthcare sector. The company offers a cloud-based platform that enhances pathologists' workflow, increases diagnostic confidence and productivity, and provides AI-driven precision in cancer diagnosis. Paige's technology also aids pharmaceutical companies in evaluating treatment options and designing new biomarkers for drug development. It was founded in 2017 and is based in New York, New York.
Ibex specializes in AI-based cancer diagnostics within the healthcare technology sector. The company offers AI-powered diagnostic solutions that assist pathologists in providing accurate and efficient cancer diagnoses. Its solutions are developed using advanced algorithms and digital workflows to detect cancer with clinical-grade accuracy. It was founded in 2016 and is based in Tel Aviv, Israel.
Owkin is an AI biotechnology company that employs artificial intelligence to improve drug discovery and development in the biopharmaceutical sector. The company specializes in AI-based identification of new treatments, clinical trial optimization, and diagnostic tool creation, while ensuring patient privacy through federated learning techniques. Owkin serves the biopharma and academic research communities. It was founded in 2016 and is based in New York, New York.
AIRA Matrix provides Artificial Intelligence solutions for the Life Sciences sector, focusing on pathology laboratory workflows. The company offers products and services that aim to improve efficiency, diagnostic accuracy, and turnaround times in pathology, as well as provide diagnostic, prognostic, and predictive options for cancer care. AIRA Matrix serves hospitals, pharmaceutical companies, contract research organizations (CROs), and research labs globally. It was founded in 2011 and is based in Mumbai, India.
Proscia focuses on the development of software for the pathology sector. The company offers include a digital pathology platform and artificial intelligence (AI)-powered applications to facilitate routine pathology operations, research breakthroughs, and patient outcomes. Proscia primarily serves the life sciences and diagnostics sectors. It was founded in 2014 and is based in Philadelphia, Pennsylvania.
Aiosyn is a healthtech company focused on developing precision pathology software solutions for the healthcare sector. The company offers AI-powered algorithms that enhance digital pathology workflows and support clinical diagnostics, as well as tools for the identification of pathology-based biomarkers for drug development. Aiosyn primarily serves the healthcare industry, including pathology laboratories and biopharmaceutical companies. It was founded in 2021 and is based in Nijmegen, Netherlands.
Loading...